Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
CYP1B1 and COMT polymorphisms not linked to increased risk
April 19th, 2005
According to a study from the United States, "Cytochrome P450 1B1 (CYP1B1) and catechol-O-methyltransferase (COMT) are important estrogen-metabolizing enzymes and, thus, genetic polymorphisms of these enzymes may affect breast cancer risk." W.Q. Wen and colleagues, Vanderbilt University, conducted "a population-based case-control study ...to assess the association of breast cancer risk with CYP1B1 and COMT polymorphisms. A meta-analysis was done to summarize the findings from this and previous studies." They said, "Included in this study were 1,135 incident breast cancer cases diagnosed from August 1996 through March 1998 among female residents of...
Source: Cancer Weekly (2005-04-19)
|
